JNJ-54175446

JNJ-54175446 is an investigational small molecule drug developed as a selective and brain-permeable antagonist of the purinergic P2X7 receptor. The P2X7 receptor is an ATP-gated ion channel implicated in neuroinflammation and the pathogenesis of mood disorders. By antagonizing this receptor, JNJ‑54175446 inhibits the release of pro-inflammatory cytokines such as interleukin‑1β (IL‑1β), both peripherally and centrally. It has demonstrated blood-brain barrier penetration and dose-dependent pharmacodynamic effects in clinical studies. The drug is being developed primarily for major depressive disorder as an adjunctive treatment and has reached phase II clinical trials. Janssen-Cilag is the originator and developer.

Other names

1627902-21-9(r)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1,4,6,7-tetrahydro-5h-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone32524GLF40UNII-32524GLF40UNII32524GLF40UNII 32524GLF40